'Analyses of R&D spending and equity investment in biotech predict that the industry is capable of weathering a drop in revenue due to lower drug prices, with no corresponding loss in new approved drugs.'

https://www.fiercebiotech.com/research/analyses-predict-reduction-drug-prices-due-inflation-reduction-act-wont-hurt-biotech